<DOC>
	<DOCNO>NCT00926627</DOCNO>
	<brief_summary>Progressive pulmonary sarcoidosis occur twenty percent patient require persistent treatment , available treatment option show considerable long-term toxicity uncertain unproven efficacy . In patient , pulmonary fibrosis pulmonary hypertension common complication major prognostic impact . Endothelin-1 ( ET-1 ) demonstrate play key role pulmonary fibrosis pulmonary hypertension , potential role pulmonary sarcoidosis . ET-1 potent vasoconstrictor promote fibrosis , cell proliferation , remodel , pro-inflammatory . Preliminary data show therapeutic potential endothelin receptor antagonist ( ERA ) bosentan sarcoidosis associate pulmonary hypertension . In light , therapeutic potential bosentan add-on treatment progressive pulmonary sarcoidosis need evaluate .</brief_summary>
	<brief_title>Safety Efficacy Study Bosentan Progressive Pulmonary Sarcoidosis</brief_title>
	<detailed_description />
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure . Male female patient age &gt; 18 &lt; 70 year . Histologically proven sarcoidosis diagnose least one year screening . Diagnosis sarcoidosis evidence pulmonary parenchymal disease chest Xray CT ( radiological stage II , III ) without pulmonary hypertension . Subjects concurrent extrapulmonary sarcoidosis encourage enrol . Progressive disease , define follow : Deterioration 312 month period prior screen least two follow criterion : increase clinical symptom ( cough , shortness breath , chest pain , fatigue hemoptysis ) . lung function : decrease 10 % TLC , FVC DLCO . worsen radiographic opacity . Have receive prestudy treatment prednisolone ( equivalent dose corticosteroid ) single agent ( â‰¥ 10 mg/day ) immunosuppressant ( methotrexate , azathioprine , cyclophosphamide , TNF inhibitor , etc . ) within 3month period immediately prior screening . Patients must stable dose medication &gt; 4 week start study medication . AST ALT value within three time upper limit normal . Ability communicate well investigator , local language , understand comply requirement study . Negative pregnancy test female patient . Adequate contraception female patient childbearing age . Known hypersensitivity excipients drug formulation bosentan . Treatment another investigational drug within 3 month prior screen . Pulmonary sarcoidosis : without disease progression define radiological stage I radiological stage IV ( pulmonary fibrosis evidence honeycombing , hilar retraction , bullae cyst ) Other cause pulmonary disease : Active tuberculosis ( positive Quantiferon test ) , fungi infection , lymphoma . Chronic obstructive pulmonary disease , asthma , interstitial lung disease sarcoidrelated Anamnesis beryllium asbestos exposition Previous smoking ( &gt; 10 PY ) , active smoker Previous administration bosentan Positive result hepatitis serology , except vaccinated subject , screen . Positive result HIV serology screen . Malignancy require chemotherapy radiation Uncontrolled disease like Chronic heart failure ( NYHA III , IV ) Diabetes mellitus ( blood glucose 2x per day &gt; 250 mg/dl , HbA1c &gt; 10 % ) Arterial hypertension ( SBP &gt; 180 mmHg ) Concomitant treatment cyclosporine A Concomitant treatment tacrolimus sirolimus Concomitant treatment glibenclamide Are pregnant , nursing , plan pregnancy trial within six month period thereafter . Have know substance dependency ( drug alcohol within 3 year screen ) . Presumed noncompliance . Legal incapacity limit legal capacity screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>endothelin receptor antagonist</keyword>
	<keyword>bosentan</keyword>
</DOC>